Nissay Asset Management Corp Japan Sells 2,711 Shares of Illumina, Inc. $ILMN

Nissay Asset Management Corp Japan decreased its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 11.9% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 20,036 shares of the life sciences company’s stock after selling 2,711 shares during the quarter. Nissay Asset Management Corp Japan’s holdings in Illumina were worth $3,523,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the company. Elyxium Wealth LLC bought a new position in Illumina during the fourth quarter worth about $25,000. Fiduciary Financial Advisors bought a new position in shares of Illumina during the 2nd quarter worth approximately $26,000. Keating Financial Advisory Services Inc. bought a new position in shares of Illumina during the 2nd quarter worth approximately $32,000. Quarry LP acquired a new position in shares of Illumina during the 3rd quarter worth approximately $32,000. Finally, Nano Cap New Millennium Growth Fund L P bought a new stake in Illumina in the 4th quarter valued at $33,000. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Illumina

In other news, SVP Christensen Jakob Wedel sold 1,033 shares of the business’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $191.52, for a total transaction of $197,840.16. Following the completion of the transaction, the senior vice president owned 14,023 shares of the company’s stock, valued at approximately $2,685,684.96. The trade was a 6.86% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 457,858 shares of the firm’s stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $200.10, for a total value of $91,617,385.80. Following the completion of the sale, the director directly owned 2,372,694 shares in the company, valued at $474,776,069.40. This trade represents a 16.18% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 1,799,688 shares of company stock valued at $379,517,231. Corporate insiders own 2.90% of the company’s stock.

Illumina Price Performance

Illumina stock opened at $213.63 on Tuesday. Illumina, Inc. has a one year low of $88.00 and a one year high of $231.81. The stock’s fifty day moving average price is $195.10 and its two-hundred day moving average price is $156.54. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.80 and a quick ratio of 1.40. The firm has a market cap of $32.26 billion, a PE ratio of 39.86, a price-to-earnings-growth ratio of 3.03 and a beta of 1.44.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, beating the consensus estimate of $1.23 by $0.08. The firm had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The business’s quarterly revenue was up 9.4% compared to the same quarter last year. During the same period last year, the firm earned $1.19 EPS. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, research analysts expect that Illumina, Inc. will post 5.36 EPS for the current fiscal year.

Analysts Set New Price Targets

ILMN has been the subject of several research reports. Leerink Partners raised their price target on Illumina from $175.00 to $210.00 and gave the company an “outperform” rating in a report on Friday, July 17th. Deutsche Bank Aktiengesellschaft lowered shares of Illumina to a “hold” rating in a research report on Wednesday, August 5th. Sanford C. Bernstein restated a “market perform” rating and set a $215.00 target price on shares of Illumina in a research note on Friday, July 31st. Zacks Research upgraded shares of Illumina from a “hold” rating to a “strong-buy” rating in a research note on Monday, August 3rd. Finally, Guggenheim increased their price target on shares of Illumina from $200.00 to $226.00 and gave the company a “buy” rating in a report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, Illumina presently has a consensus rating of “Hold” and a consensus target price of $188.40.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.